BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1258 related articles for article (PubMed ID: 19047291)

  • 1. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
    Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
    J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
    Monclair T; Brodeur GM; Ambros PF; Brisse HJ; Cecchetto G; Holmes K; Kaneko M; London WB; Matthay KK; Nuchtern JG; von Schweinitz D; Simon T; Cohn SL; Pearson AD;
    J Clin Oncol; 2009 Jan; 27(2):298-303. PubMed ID: 19047290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.
    Naranjo A; Irwin MS; Hogarty MD; Cohn SL; Park JR; London WB
    JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
    Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB
    J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
    Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson AD; Maris JM
    Br J Cancer; 2009 May; 100(9):1471-82. PubMed ID: 19401703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Moroz V; Machin D; Hero B; Ladenstein R; Berthold F; Kao P; Obeng Y; Pearson ADJ; Cohn SL; London WB
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28359. PubMed ID: 32472746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG).
    Ohira M; Nakamura Y; Takimoto T; Nakazawa A; Hishiki T; Matsumoto K; Shichino H; Iehara T; Nagase H; Fukushima T; Yoneda A; Tajiri T; Nakagawara A; Kamijo T
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
    Liang WH; Federico SM; London WB; Naranjo A; Irwin MS; Volchenboum SL; Cohn SL
    JCO Clin Cancer Inform; 2020 Oct; 4():895-905. PubMed ID: 33058692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
    Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
    J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
    J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma: validation of the INRG classification system in a small series.
    Ramos Elbal E; Galera Miñarro AM; Llinares Riestra ME; Bermúdez Cortés M; Fuster Soler JL
    Clin Transl Oncol; 2019 Dec; 21(12):1776-1780. PubMed ID: 30949929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
    Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
    BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
    London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
    J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective study.
    Yang DD; Liu C; Gao J; Hu QJ; Liang Y; Liu J
    Eur J Pediatr; 2023 May; 182(5):2189-2196. PubMed ID: 36856889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
    Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD
    J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.